Grizzly Bulls
Following Medpace Holdings?

Medpace Holdings

Financial performance and company analysis from public filings and market data.
MEDPNasdaq
Medpace Holdings Common Stock
Latest close
$654.08
Oct 22, 2026 · completed session
Company website ↗Compare companies

Company snapshot

A consistent view of the latest supported company value and reported operating results.

Market cap
$18.68B
Shares reported Jul 17, 2026
Revenue (TTM)
$2.84B
Through Sep 30, 2026
Net income (TTM)
$517.8M
Through Sep 30, 2026
Free cash flow (TTM)
$667.6M
Through Sep 30, 2026

Fundamental lens

Four transparent questions from retained financial evidence. Each result stands on its own; Grizzly Bulls does not combine them into a score, ranking, or recommendation.

Profitability
Profitable
Is trailing-twelve-month net income positive?

Trailing-twelve-month net income is positive. As of 2026-09-30.

Net income (TTM): $517.8M
Cash generation
Positive free cash flow
Is trailing-twelve-month free cash flow positive?

Trailing-twelve-month operating cash flow less capital expenditures is positive. As of 2026-09-30.

Free cash flow (TTM): $667.6M
Liquidity
Current liabilities above assets
Do reported current assets cover reported current liabilities?

Reported current liabilities exceed reported current assets on the latest comparable retained balance sheet. As of 2026-09-30.

Current assets: $1.2B · Current liabilities: $1.5B
Recent operating direction
Unknown
What changed in the latest comparable reported results?

Comparable retained change history is not available through this reader.

How this lens works

Profitability uses only the sign of retained trailing-twelve-month net income. Cash generation uses only the sign of retained trailing-twelve-month free cash flow, defined as operating cash flow less capital expenditures.

Liquidity compares current assets with current liabilities only when both are retained for the same reporting date. It does not infer liquidity from differently dated balance sheets.

Recent operating direction uses the latest supported material financial event when comparable history exists. The existing change methodology requires at least a 10% absolute change or a sign/zero transition and compares quarterly results only with the same fiscal quarter year over year.

Descriptive decision support only. No composite score, hidden weighting, cross-company rank, or investment recommendation is produced.

Market summary

Completed-session reference prices from IEX for Oct 22, 2026.

Open
$657.97
Completed session
High
$682.35
Completed session
Low
$648.14
Completed session
Close
$654.08
Completed session

Price statistics

1M close return
3.6%
Through Oct 22, 2026
3M close return
24.0%
Through Oct 22, 2026
50-session reference-close average
$609.68
Through Oct 22, 2026

IEX historical data reflects IEX activity only and is presented as a source-scoped reference point, not as consolidated U.S. market history. Prices are unadjusted. Price returns exclude dividends and are not total returns. Historical statistics appear only when the retained source-session chain is complete and no split-like share-basis discontinuity is detected for that calculation window.

Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Price history

Five years of adjusted closing-price history for this listing, shown as historical context rather than a live quote.

Medpace Holdings five-year adjusted closing-price history1255 observations from Oct 25, 2021 to Oct 23, 2026. Values range from $130.20 to $669.20.$712.31$556.01$399.70$243.39$87.08Oct 25, 2021Jan 25, 2023Apr 24, 2024Jul 28, 2025Oct 23, 2026
Provider-adjusted regular-session closes · Oct 25, 2021–Oct 23, 2026 · USD per share
Market history source
About this price history

The chart uses the market provider's adjusted daily close for the current listing. It does not stitch predecessor listings and does not represent total return, benchmark performance, or historical valuation.

Listing & sources

Ticker: MEDP · Exchange: Nasdaq · Medpace Holdings Common Stock

SEC issuer CIK: 0001668397

Company Research Map

These reviewed encyclopedia concepts are supported by public-company evidence for this business. Operating-model groups show how the reported concepts fit together without implying that every metric in the broader model is reported by this issuer.

Research coverage

Start with an operating model, then move into the supported concepts and economic bridges below. Coverage counts describe reviewed evidence links for this issuer, not standardized KPI completeness.

Contract Research Organization Economics8 of 10 reviewed concepts2 economic bridges

Contract Research Organization Economics

8 reviewed concepts

Connect clinical-research awards, cancellations, book-to-bill, backlog policy and conversion, near-term revenue visibility, and reimbursed pass-through activity across contract research organizations.

How these metrics connect

These bridges come from the reviewed operating model. Linked concepts have public-company evidence for this issuer; broader bridge coverage remains explicit when the model contains additional concepts.

Awards, cancellations, and demand coverage
3 of 3 reviewed concepts

Net new awards or bookings incorporate cancellations, while book-to-bill compares that net commercial inflow with current revenue. Together they show whether newly won work is replenishing the revenue base without treating gross wins as guaranteed future revenue.

Backlog quality, timing, and conversion
4 of 5 reviewed concepts

Backlog captures expected contracted work, inclusion policy defines which work qualifies, RPO preserves a separate accounting boundary, next-twelve-month backlog shows near-term timing, and backlog conversion indicates how quickly the booked work becomes revenue.

Explore the broader operating model

These reviewed concepts belong to the same operating model but are not currently linked to this issuer. That is a research-navigation boundary, not evidence that the company does not report an equivalent metric.

Compare reviewed company examples

These companies share at least two reviewed concepts with this issuer in the same operating model. The company links are research handoffs, not a peer ranking, and reported metric definitions can differ. When both companies are eligible for the published stock-comparison tool, a separate financial-comparison link is available below; it compares supported company financials, not normalized operating-model KPIs.